Rising concern over the spread of the Zika virus, crystallized by Monday's WHO labeling of it as a public health emergency, has jumpstarted efforts at Sanofi SA, Glaxosmithkline plc, Newlink Genetics Corp., Mymetics Corp. and Valneva SE to develop new vaccines against the dengue-related virus.